In lung cancer, our group has recently shown that LH2 switches LCCs to more stable HLCCs in tumor stroma, which results in increased stromal stiffness, enhanced tumor growth, and metastasis11, suggesting that LH2 is a potential therapeutic target for preventing tumor metastasis. Here, PLOD2 is linked to lung cancer.